Comparison of anti-inflammatory effects of rivaroxaban versus dabigatran in patients with non-valvular atrial fibrillation (RIVAL-AF study) -Multicenter randomized study
Latest Information Update: 07 Nov 2021
At a glance
- Drugs Rivaroxaban (Primary) ; Dabigatran etexilate
- Indications Arteriosclerosis; Embolism and thrombosis; Stroke
- Focus Biomarker; Pharmacodynamics
- Acronyms RIVAL-AF
- 31 Aug 2016 Status changed from active, no longer recruiting to completed,according to the results presented at the ESC Congress 2016: Annual Congress of the European Society of Cardiology
- 04 Aug 2015 According to the ClinicalTrials.gov record, planned primary completion date changed from 1 May 2015 to 1 Oct 2015.
- 04 Jan 2015 According to the University Hospital Medical Information Network - Japan record, planned number of patients changed from 150 to 200.